MiniMed Group Inc (MMED) Stock Analysis
Verdict: WATCH (do not buy)
Top-line growth and target bumps drive momentum, but $420M FCF burn and structural unprofitability make risk/reward unfavorable at $23.84.
Investment score: 49/100
Analysis as of
Is MiniMed Group Inc stock worth reviewing? AI model thesis
MiniMed Group surged 46% over the last 30 days to $23.84 following Q1 sales of $843M (+16.6% YoY), sparking target increases from Wall Street analysts up to $28.00. However, persistent earnings misses and severe FCF burn (-$420M in FY26) limit the model's confidence in further expansion past its 52W high of $24.43 without operational margin improvement.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
MiniMed Group Inc opportunities and risks
What speaks for MMED
- Accelerating Q1 sales growth of 16.6% YoY to $843M
What speaks against MMED
- Severe free cash flow burn of -$420M in FY2026
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MMED | n/a | 2.1x | 109.0x | 53.5% | -16.0% | -2.8% |
| MDLN | 42.5x | 1.0x | 16.2x | 25.0% | 2.3% | 6.5% |
| SOLV | 11.2x | 1.9x | 8.0x | 54.7% | 17.3% | -0.7% |
| COO | 59.9x | 3.3x | 18.6x | 64.4% | 5.6% | 4.1% |
| ALGN | 27.8x | 2.8x | 13.3x | 66.5% | 10.0% | 6.6% |
| Peer median | 35.1x | 2.3x | 14.8x | 59.5% | 7.8% | 5.3% |
Frequently asked questions about MiniMed Group Inc (MMED)
Is MMED stock a good investment?
The cached TradeMates AI model rates MiniMed Group Inc as WATCH (do not buy) with an investment score of 49/100. MiniMed Group surged 46% over the last 30 days to $23.84 following Q1 sales of $843M (+16.6% YoY), sparking target increases from Wall Street analysts up to $28.00. However, persistent earnings misses and severe FCF burn (-$420M in FY26) limit the model's confidence in further expansion past its 52W high of $24.43 without operational margin improvement. This is algorithmic model output, not personal investment advice.
Is MMED stock a buy?
The TradeMates model verdict for MMED is WATCH (do not buy) with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.